Science-Driven Innovation in Dermatology Drug Development

The company’s robust medical dermatology pipeline includes both late-stage and early-development product candidates that target specific unmet needs in two of the largest growing immuno-dermatology markets, psoriasis and atopic dermatitis, as well as other large markets, including vitiligo, primary focal hyperhidrosis, and acne. Dermavant is developing its lead product candidate, tapinarof (DMVT-505), as a differentiated therapeutic aryl hydrocarbon receptor modulating agent (TAMA) topical cream for the treatment of psoriasis and atopic dermatitis, which affect approximately 8 million and 26 million people in the United States, respectively.

Strategic Collaborators

Dermavant Sciences has formed important alliances with companies who share our commitment to develop innovative dermatology drug candidates into medicines that will change the lives of patients with atopic dermatitis and other inflammatory skin diseases.